PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Positive gross profit growth while TRVN is negative. John Neff would see a clear operational edge over the competitor.
27.93%
Positive EBIT growth while TRVN is negative. John Neff might see a substantial edge in operational management.
27.93%
Positive operating income growth while TRVN is negative. John Neff might view this as a competitive edge in operations.
29.77%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
30.61%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.61%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.13%
Share reduction more than 1.5x TRVN's 12.07%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.13%
Diluted share reduction more than 1.5x TRVN's 12.07%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
32.67%
Similar OCF growth to TRVN's 32.95%. Walter Schloss would assume comparable operations or industry factors.
32.86%
FCF growth similar to TRVN's 32.71%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
10Y OCF/share CAGR above 1.5x TRVN's 41.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.83%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
20.41%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
95.17%
Positive 10Y CAGR while TRVN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.59%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
2.82%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
170.99%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-42.91%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.55%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while TRVN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while TRVN stands at 2.64%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.